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Identifying the specific functional regulator of integrin family molecules in cancer cells is critical
because they are directly involved in tumor invasion and metastasis. Here we report high expression
of PLOD2 in oropharyngeal squamous cell carcinomas (SCCs) and its critical role as a stabilizer of in-
tegrin b1, enabling integrin b1 to initiate tumor invasion/metastasis. Integrin b1 stabilized by
PLOD2-mediated hydroxylation was recruited to the plasma membrane, its functional site, and accel-
erated tumor cell motility, leading to tumor metastasis in vivo, whereas loss of PLOD2 expression
abrogated it. In accordance with molecular analysis, examination of oropharyngeal SCC tissues
from patients corroborated PLOD2 expression associated with integrin b1 at the invasive front of
tumor nests. PLOD2 is thus implicated as the key regulator of integrin b1 that prominently regulates
tumor invasion and metastasis, and it provides important clues engendering novel therapeutics for
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Head and neck cancers are the sixth most common malignant tumors worldwide. They are mainly treated
with extended resection or radiation/chemotherapy, but functional deteriorations in swallowing, vocaliza-
tion, and respiration lead to clinical decline in quality of life (QOL). Even in cases of combined surgical treat-
ment with radiation therapy and chemotherapy, local recurrence including primary lesion and surrounding
lymph nodes, is usually observed in approximately 30% of the patients. As distant metastases, as in the
lung, can be seen in 25% of cases, recurrence and therapeutic resistance are very conspicuous. The
5-year survival rate in advanced cases of stage III and above is about 40%; thus the patients still present
a poor prognosis (Laramore et al., 1992). Recently, cetuximab, a molecular targeting agent, has been
administered in combination with cisplatin to patients with head and neck malignancies, showing some
benefit to outcomes. However, it remains that subjects suffer from serious side effects such as dermatitis
and mucositis, and novel avenues for cancer therapeutics are needed for improved antitumor properties
and patient QOL (Bonner et al., 2006).
Previous studies revealed that 2-oxoglutarate and the iron-dependent dioxygenases superfamily function
as a hydroxylase/demethylase and that they hydroxylate or demethylate molecules such as transcription
factor, histones, and DNA as substrates. Indeed, it has been reported that these enzymes play various roles
in cell cycle and gene expression and control of invasion/metastasis of cancer cells in multiple cell lines via
modified molecules (Markolovic et al., 2015).
There are some reports that procollagen lysyl hydroxylase (PLOD), which belongs to this superfamily, is
involved in the hydroxylation of collagen molecules as the only target molecule identified to date, and it
is considered to be an essential enzyme for cross-linking reaction between collagen molecules outside
the cell (Wu et al., 2006). PLOD is composed of an N-terminal endoplasmic reticulum-body translocation
signal, a hydroxyl-catalyzed domain at the C-terminus, and hydroxylates lysine residues located in the ter-
minal region of the collagen precursor in the ER.
Currently, three members of the PLOD family molecular group are found to share high homology: PLOD1,
PLOD2, and PLOD3 (Valtavaara et al., 1997; Passoja et al., 1998a). Tissue expression analysis by Northern
blot showed that PLOD2 and PLOD3 had tissue-specific expression unlike the broad expression of PLOD1.iScience 23, 100850, February 21, 2020 ª 2020 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Expression of the Various Hydroxylases in Oral SCC Cells
(A) The expression level of mRNAs in oral SCC cells was determined by quantitative PCR compared with that of HaCaT. Data are meansG s.d. from three
biological replicates (*p < 0.05, Student’s t-test).
(B) Protein expression of PLOD family in SCC lines and HaCaT by immunoblotting.
(C) Immunofluorescence of PLOD2 in oral SCC lines (HSC-2, HSC-3, and Ca9-22) and non-neoplastic keratinocyte (HaCaT). Colocalization of PLOD2 with ER
marker (ER-GFP) was indicated by arrowhead. Nuclei were stained with Hoechst 33258. Scale bar = 20 mm.
(D) RNA interference (siRNA)-mediated knockdown of PLOD in oral SCCs demonstrated the attenuated protein expression by immunoblotting.
(E) GFP-expressing SCC cells were transfected with control siRNA (siCtrl) or with PLOD-siRNA (siPLOD1, siPLOD2, and siPLOD3). Cell migration was
evaluated by wound healing assay. Images were taken at 0 and 24 h after wound formation (scale bar = 400 mm). The wound width was estimated using
fluorescence microscopic images. Each symbol represents siCtrl (circle, black), siPLOD1 (square, blue), siPLOD2 (triangle, red), and siPLOD3 (cross, green).
Asterisk indicates p < 0.05 as compared with siCtrl. Data are means G s.d. from three technical replicates for one biological replicate.In particular, PLOD2 has been reported to be induced in response to differentiation of bone marrow stro-
mal cells (Valtavaara et al., 1998; Uzawa et al., 1999). Genemutations in PLOD1 and PLOD3 have been iden-
tified in the case of Ehlers-Danlos syndrome (fragile skin, hematomas, and joint hypermobility), whereas
PLOD2 mutations are clinically reported as involved in the Bruck syndrome characterized by imperfect
bone formation (Walker et al., 2004; van der Slot et al., 2003).
Furthermore, based on the previous studies, PLOD2 has been reported to be specifically induced by acti-
vation of transcription factor HIF-1a in response to hypoxia and TGF-b1 stimulation on tumor stroma, can-
cer cells (breast cancer, hepatocellular carcinoma), and sarcoma (mouse sarcomamodel) (Chen et al., 2015;
Gilkes et al., 2013a, 2013b; Eisinger-Mathason et al., 2013).
It is known that collagen secretion and remodeling of extracellular matrix (ECM) are accelerated especially in
cancer stromal cells, leading to invasion and metastases of cancer cells (Gilkes et al., 2013a). The association
of HIF-1a-dependent increase in expression of PLOD2 and epithelial mesenchymal transition (EMT) has been
established in human glioma cells, andgliomapatients with high expression of PLOD2 showed a poor prognosis
(Xu et al., 2017). However, the intracellular substrate and tumorigenic activity of PLOD2 expressed in cancer cells
remains unclear, especially in refractory cancers, such as oral, head, and neck cancers.
In this study, apart from tumor microenvironmental factors, we focused on biological function of PLOD2 on
cancer cell itself using oral squamous cell carcinoma (SCC) lines as a model because they are high in PLOD2
expression, especially in tumor invasion/metastasis highlighting specific interaction between PLOD2 and
integrin b1. We have found that PLOD2 induces the hydroxylation of integrin b1, which plays an essential
role in the stability and cellular localization of integrin b1 for its functional activation. The integrin b1 re-
quires specific interaction with PLOD2, which will lead to greater understanding of molecular mechanisms
for cancer invasion/metastasis and foster innovation in therapies against refractory malignancies.
RESULTS
Specific Upregulation of PLOD2 and Its Effect on Cellular Motility of Oral SCC Cells
Since the 2-oxoglutarate and iron-dependent dioxygenases have been classified into several groups according
to the target amino acid residue, such as proline hydroxylase, asparagine/aspartate hydroxylase, etc., we first
examined their expression in each category to identify specific hydroxylases highly expressed only in SCC lines
from the oral cavity, in contrast to the non-neoplastic cellular counterpart (non-tumorigenic immortalized kera-
tinocyte), HaCaT. Three representative human oral SCC lines (HSC-2, HSC-3, Ca9-22) derived from different pa-
tients were examined in comparison with HaCaT, and gene expression of typical hydroxylases for each category
was examined by a semiquantitative RT-PCRmethod (Figure S1A). The expression of JMJD2A, JMJD6, EGLN2,
MINA53,NO66, HIF1AN, FTO, and TET1 did not show a significant difference between the tumor cells and Ha-
CaT. On the other hand, the expression of PLOD2, EGLN1, EGLN3, OGFOD1, ASPH, and ALKBH3 revealed
certain differences in expression among these cell lines, especially in that the mRNA level of PLOD2 in the
SCC lines showed the most prominent and consistent increase at four to eight times compared with HaCaT
(Figures S1A and 1A). This upregulation of PLOD2mRNA in tumor cells was also corroborated by protein levels
in immunoblot analysis even among the lysyl hydroxylase family including PLOD1 andPLOD3 (Figure 1B). Immu-
nofluorescence analysis with anti-PLOD2 antibody revealed that endogenous PLOD2 was predominantly local-
ized to the ER which was confirmed by GFP-labeled ERmarker (Figure 1C). Thus, tumor-specific upregulation of
the expression was observed only in PLOD2 among the examined hydroxylase and demethylase family, and the
mRNA and protein levels of PLOD1 and PLOD3 were not specifically elevated in the tumor cells although they
are categorized to the same family.iScience 23, 100850, February 21, 2020 3
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Figure 2. PLOD2 Is Essential for Stabilization of Integrin b1
(A) Immunofluorescence revealed expression, and localization of CDH1 was not affected by siPLOD2-treatment in SCC cells.
(B) Expression and intracellular localization of integrin b1 of the SCC cells was examined at 48 h after treatment with siPLOD2. Cytoskeleton and nuclei were
stained with phalloidin and Hoechst, respectively. Scale bar = 20 mm.
(C) Expression of integrin b1, CDH1, and SNAIL in the siPLOD2-transfected cells by immunoblotting using anti-PLOD2, anti-integrin b1, anti-CDH1, and anti-
SNAIL Ab, respectively.
(D) Semiquantitative expression of integrin b1 mRNA by RT-PCR with or without siPLOD2-treatement.
(E) Comparative ratio of integrin b1 mRNA in siPLOD2-treated cells based on the quantitative PCR results. Quantitative results are meanG s.d. from three
biological replicates (n.s. = not significant, Student’s t-test).
(F) Restoration of integrin b1 by treatment with MG132 and chloroquine (CHQ). HSC-2 cells pretreated with siPLOD2 were examined for integrin b1
expression 18 h after treatment with MG132 (1 nM) or CHQ (50 mM), respectively. Expression of integrin b1 protein by immunoblotting (upper panel),
intracellular localization of integrin b1 by immunofluorescence using anti-integrin b1 Ab (lower panel). Integrin b1 (red) was merged with lysosome marker
(Lyso-GFP). Scale bar = 20 mm.
(G) Effect of PLOD2 mutant lacking the catalytic domain (DPKHD) to integrin b1. Integrin b1 of the HSC-2 transfected with myc-tagged PLOD2 lacking the
hydroxylase domain (DPKHD) compared with that of the cells transfected with the WT. Reduction of integrin b1 detected by immunoblotting (upper panel)
and the loss of plasma membrane localization indicated by arrowhead with immunofluorescence (lower panel). Scale bar = 20 mm.
(H) Wound healing assay revealed cell migration was affected in the DPKHD-transfected cells as shown in the graph (upper panel) and migratory images
(lower panel). Each symbol in the graph represents empty vector (circle, black), PLOD2WT (square, blue), and PLOD2DPKHDmutant (triangle, red). Data are
means G s.d. from three technical replicates for one biological replicate (*p < 0.05, Student’s t-test as compared with empty vector).Based on these results, we next studied the cellular motility of the SCC cells, HSC-2, HSC-3, and Ca9-
22, treated with specific siRNA against PLOD2 (siPLOD2) in comparison with the cells treated with si-
PLOD1 or siPLOD3. Specificity of the siRNA for each PLOD isoform (siPLOD1, siPLOD2, and siPLOD3)
was confirmed by immunoblotting, which demonstrated that knockdown by these siRNAs did not
affect other isotypes (Figures S1B and 1D). In the wound-healing assay, each stable GFP-expressing
clone established from parental HSC-2, HSC-3, and Ca9-22 was employed for evaluation. Mobilization
of each clone, visualized by fluorescence microscope 24 h after treatment with the siRNA, revealed
that only attenuated expression of PLOD2 significantly affected cellular migration among these three
SCC cells, whereas neither PLOD1-knockdown nor PLOD3-knockdown critically disturbed migration of
the tumor cells (Figure 1E, upper images and Figure S1B). Inhibition of wound closure was over 50% in
siPLOD2-treated cells at 24 h following siRNA treatment (Figure 1E, lower graphs); however, the MTT
assay indicated that tumor cell proliferation was not affected by siRNA-treatment in all PLOD isoforms
(Figure S1C). These data implied that PLOD2 might be deeply involved in regulating tumor cell
motility.Crosstalk between PLOD 2 and Integrin b1 in Cellular Motility
On the basis of these findings, we focused on the specific role of PLOD2 in tumor cell motility. Generally,
acceleration of cell mobility is closely related to invasive properties of tumor cells, and we examined
whether expression of E-cadherin (CDH1) as a marker of epithelial-mesenchymal transition (EMT) was
altered with or without siPLOD2-treatment of the SCC cells. We found that PLOD2-knockdown did
not affect the expression and membrane localization of CDH1 for all SCC cells (Figures 2A and S2A).
Because all of these three SCC lines highly express integrin b1 as one of the critical motor molecules
for invasion, we next examined the effect of PLOD2 on integrin b1 therein. In siPLOD2-treated tumor
cells, lack of filopodia development was observed as a morphological change as confirmed by phalloidin
staining, and a marked decrease in integrin b1 was revealed, in contrast to the cells treated with control
siRNA (Figures 2B, S2B, S2C, and S3). This phenomenon was not seen in siPLOD1- or siPLOD3-treated
cells (Figure S1D). The siPLOD2-treated tumor cells with decreased integrin b1 showed no altered
expression of CDH1 or SNAIL, suggesting the PLOD2 seemed not to be involved in EMT at least in these
SCC cells (Figures 2C and S4A). Involvement of integrin b1 in migration of these SCC cells was demon-
strated by knockdown assay using siIntegrin b1 (Figures S4B and S4C). Taken together, our data indicate
that integrin b1 appears directly regulated by PLOD2 for these tumor cells in an EMT-independent
manner.
Next, to clarify whether PLOD2 affects induction of integrin b1 mRNA, or directly modifies the integrin b1
protein, RT-PCR was first performed to examine fluctuations in mRNA levels. Ultimately, no significant alter-
ation in integrin b1 mRNA expression with or without siPLOD2 introduction was detected in SCC cells,
which was further confirmed by qPCR (Figures 2D and 2E). Therefore, siPLOD2 did not affect induction
of integrin b1 mRNA, i.e. the result suggested that integrin b1 protein might be persistently produced in
tumor cells but may require a certain modification by PLOD2 for stabilization.iScience 23, 100850, February 21, 2020 5
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Figure 3. Specific Coupling of Integrin b1 with PLOD2
(A) The construction of PLOD2 expressor fused Monti-red tag (PLOD2-Red) and integrin b1 expressor fused Ash tag (Integrin b1-Ash) (left panel). Schematic
representation of mechanism for intracellular fluorescent dot formation in response to specific protein-protein interaction (right panel).
(B) Marked aggregation of fluorescent dots was detected only in the HeLa cells cotransfected with PLOD2-Red and Integrin b1-Ash. Scale bar = 20 mm.
(C) The fluorescent dots were merged with GFP-labeled ER marker (ER-GFP). Arrowhead indicated each PLOD2, ER-GFP, and colocalized proteins in the
transfected HeLa cells, respectively. Scale bar = 20 mm.
(D) The fluorescent dots were observed at lamellipodia of the PLOD2-Red-Integrin b1-Ash cotransfected cells or the Integrin b1-Red-PLOD2-Ash
cotransfected cells. Hatched box indicated hyperview field in the right. Scale bar = 20 mm.
(E) Domain organization of the FLAG epitope tagged-Integrin b1 expressor, Myc epitope-tagged PLOD2mutant expressor lacking PKHD domain (DPKHD)
used in the immunoprecipitation assay.
(F) Integrin b1 was coprecipitated both with WT-PLOD2 and DPKHD-PLOD2 in HEK293T cells. Expression of each PLOD2 expressor and EGFP expressor as a
control in whole cell lysates (left), immunoprecipitated PLOD2, and its variant (probed with anti-Myc Ab) using anti-Flag Ab for precipitation (right). IgG
heavy chain (H.C.) and light chain (L.C.) are shown.Following the recent study reporting degradation of integrin a at lysosome post-ubiquitination (Lobert
et al., 2010), we examined the effects of proteasome inhibitor, MG132, and chloroquine (CHQ)—which is
known to interfere with endocytosis processes and with ligand delivery to the lysosome (Erbacher et al.,
1996)—as to whether they might restore the integrin b1 protein in siPLOD2-treated tumor cells. Immu-
noblotting demonstrated that both MG132 and CHQ successfully restore integrin b1 to the level of
the control siRNA-treated cell as shown in Figure 2F (upper panel) and Figure S5A and that intracellular
localization of integrin b1 was observed in the siPLOD2-introduced cells treated with MG132 and with
CHQ, whereas membranous integrin b1 was only restored in MG132-treated cells (Figure S5B). The inci-
dence of lysosome localization of integrin b1 remains at the same level in all cases (Figure 2F lower panel
and Figure S5C). Based on this finding, the role of PLOD2 as a hydroxylase was examined with respect to
stability of integrin b1 in the wild-type PLOD2-transfected HSC-2 vs. the DPKHD-PLOD2-transfected cell
(DPKHD; DLysyl hydroxylase/prolyl 4-hydroxylase domain, inactive form lacking the catalytic domain of
PLOD2) (Pirskanen et al., 1996; Passoja et al., 1998b; Heikkinen et al., 2000; Ruotsalainen et al., 2006;
Kati et al., 2007). Significant enhancement of integrin b1 was not observed in the wild-type PLOD2-trans-
fected HSC-2 but its membrane expression (filopodial localization) was prominently enhanced (Figure 2G,
lower panel images) due to the stabilization of integrin b1 protein by sufficient PLOD2. On the other
hand, immunoblotting revealed reduction of integrin b1 in the DPKHD-PLOD2-transfected cells
compared with empty vector or wild-type PLOD2-transfected HSC2 (WT), and loss of the membranous
integrin b1 was observed in contrast to the WT and the vector cells (Figure 2G). In this regard, decrease
of integrin b1 in DPKHD-PLOD2-transfected cells was supposed to be due to destabilization of integrin
b1 lacking active PLOD2, which was explained by MG132 assay shown in Figure S5D. Cellular motility of
the DPKHD-PLOD2-transfected cells was significantly attenuated as shown by wound-healing assay
(Figure 2H). These data imply that hydroxylase activity of PLOD2 was required for protein stability and
functional localization of integrin b1.PLOD2 Regulates Intracellular Localization of Integrin b1 Through Their Coupling
To examine whether PLOD2 specifically regulates intracellular localization of integrin b1, "Fluorescent
based technology detecting Protein-Protein Interaction in living cells" (the Fluoppi system) was
employed to visualize the movement of integrin b1 in the presence of PLOD2 (Figure 3A). When the
two proteins of interest specifically bind to each other, it yields aggregated fluorescence foci (red
colored dots) inside cells under the Fluoppi system. As shown in Figure 3B, large fluorescence foci in
HeLa cotransfected with PLOD2-Red and integrin b1-Ash demonstrated specific binding of PLOD2 to in-
tegrin b1 within cells. Further we did semiquantification of fluorescent dot intensity on Fluoppi speci-
mens between PLOD2-alone-expressing cells and integrin b1–PLOD2-coexpressing cells (Figures S6A
and S6B). We also repeated Fluoppi assay to obtain clear image of fluorescent dot formation only on
the integrin b1–PLOD2 cotransfection into the PLOD2-knockout cells (Figure S6C). Tracking the
PLOD2-integrin b1 complex by Fluoppi system using integrin b1-Red expressor in combination with
PLOD2-Ash, the fluorescent foci were first colocalized with ER-GFP in the early phase of transfection,
suggesting they were at the ER (Figures 3C and 3D) and then Monti-red-labeled integrin b1 protein
transited to filopodia and the plasma membrane in the cotransfected cells (Figure 3D). Immunoprecip-
itation assay using anti-Flag Ab on the cotransfected HEK293T cell lysates indicated binding of integrin
b1 both to full-length PLOD2 and DPKHD-PLOD2, which demonstrated direct binding of these two pro-
teins, and integrin b1 bound to the site outside of the PKHD domain of PLOD2 (Figures 3E and 3F).iScience 23, 100850, February 21, 2020 7
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Figure 4. Hydroxylation of Integrin b1 in Presence of PLOD2 and Its Significance in Intracellular Localization of Integrin b1
(A) LC/MS of integrin b1 purified from lysate of the 293T cells coexpressing integrin b1-Flag andWT-PLOD2 in comparison with that from the cells expressing
integrin b1-Flag and DPKHD-PLOD2. The main peaks of integrin b1 were highlighted with the hatched box.
(B) Hyperview of the highlighted peaks. Arrowhead represented the fragment of integrin b1 (position of #651-658 a.a. containing three lysines; AFNKGEKK)
from theWT-PLOD2-transfected or form theDPKHD-PLOD2-transfected lysate, which showed shift of the peak between these two integrin b1 (spectra; 484.5
to 486 m/z).
(C) Recombinant PLOD2-6xHis protein from HEK293T was purified in 150 mM imidazole using cobalt resin. Purification of PLOD2 was confirmed by
Coomassie staining and immunoblotting.
(D) Hydroxylation reaction of PLOD2 was carried out in vitro as described in Methods. Collagen peptides or no peptide substrates were used as controls for
reaction. Data are means G s.d. from three technical replicates for one biological replicate (*p < 0.05, Student’s t-test).
(E) Expression of integrin b1 mutants replacing Lys#654 to Ala (K654A), Lys#657 to Ala (K657A), Lys#658 to Ala (K658A), or the triple Ala-substituted mutant
replacing the lysine (3KA).
(F) Intracellular localization of the integrin b1 of these three mutants on HSC-2. Arrowhead indicated integrin b1 at the plasma membrane. Only in the
transfectant with triple Ala mutant did integrin b1 lack its membranous localization. Scale bar = 20 mm.Further immunoprecipitation experiments of endogenous PLOD2 in HSC-2 cells revealed an interaction
with the immature integrin b1 (Figure S6D).Direct Hydroxylation of Integrin b1 by PLOD2 for Its Activation
Because the result of the specific binding between PLOD2 and integrin b1 would indicate that integrin b1
might be a substrate for PLOD2, hydroxylation of the integrin b1 protein purified from the lysate of the 293T
transfected with wild-type (WT) PLOD2 was analyzed by mass spectrometry (LC/MS) using the integrin b1
derived from DPKHD-PLOD2 transfected cells. The main spike, indicated with the hatched box in the over-
viewed LC/MS chromatogram of integrin b1 from the cotransfected cells with integrin b1 and WT-PLOD2
(Figure 4A), contained the unique spike (indicated by arrow) representing the molecular weight of triple
lysine hydroxylation (encoded amino acids between 651 a.a. and 658 a.a., ‘‘AFNKGEKK’’), which was not
observed in the integrin b1 protein from the integrin b1-DPKHD-PLOD2 cotransfected sample (Figure 4B;
hyperview of 4A). The shift of the integrin b1 peak indicated by the arrow in theWT-PLOD2 cotransfected
sample is two-fold higher than that of the integrin b1 in the DPKHD-PLOD2 cotransfected sample
(Figure 4B). Additionally, we performed an experiment monitoring the activity of PLOD2 employing sub-
strate peptides according to the previous reports (Takaluoma et al., 2007; Guo et al., 2017). The result
showed specific increase of succinate derived from a-ketoglutarate and substrate (integrin b1 substrate
peptide.; AFNKGEKK) incubated with purified PLOD2 as well as positive control sample using collagen
peptide (IKGIKGIKG) sample (Figures 4C and 4D). The stability of integrin b1 harboring the single
Lys-replacement with Ala (K564A, K657A, and K658A) did not seem significantly impaired inside cells trans-
fected with each integrin b1 mutant; however, triple Lys-mutated integrin b1 (K564A + K657A + K658A)
seemed markedly unstable (Figure 4E). Moreover, the triple Lys-mutative integrin b1 was not recruited
to the plasma membrane in the transfected HSC-2 cells, in contrast to the cells with the single Lys-mutative
integrin b1, which still retained its membranous localization as well as in those with WT-integrin b1 (Fig-
ure 4F). In this regard, flow cytometry analysis revealed that approximately 20% of the WT-transfected
BHK cells showed plasma membrane expression of integrin b1, whereas no significant number of cells
showed membrane expression of integrin b1 in the triple K-A mutant-transfected cells, which indicated
loss of membrane localization without PLOD2 activity (Figures S7A and S7B). Thus, the magnitude of
hydroxylation on integrin b1 by PLOD2 might be critical for its intracellular stability.PLOD2 Facilitates Metastasis of SCC Cells In Vivo
Based on these findings, we examined whether PLOD2-affected invasion/metastasis of SCC cells in vivo
using the intrathoracic metastatic mouse model xenografted with HSC-2 cells. Stably GFP-expressing
HSC-2 cells from the PLOD2-knockout clone (PLOD2-KO; KO#31, Figure S8A) were xenografted into the
thoracic cavity of athymic nude (nu/nu) mice and evaluated for development of metastatic foci 40 days
post-implant in comparison with mice xenografted with parental HSC-2 cells (PLOD2-WT). As to cellular
behaviors, PLOD2-KO (KO#31) carrying the heterozygous knockout of PLOD2 did not show significant
differences in cellular growth compared with parent HSC-2 (Figure S8B), but endogenous expression of in-
tegrin b1 was seriously attenuated (Figure S8C). In the KO#31 clone, plasma membrane localization of in-
tegrin b1 was also disturbed, which suggested impaired function of integrin b1 (Figure S8D). Reflecting
these results, cellular motility of KO#31 was also seriously decreased in comparison with the parental
HSC-2 cells (Figure S8E, image and graphs).Whereas, using PLOD2-KO clone (#31) of HSC-2, we performed
rescue experiment by reintroducing wild-type PLOD2. The result showed the revertant (revPLOD2)iScience 23, 100850, February 21, 2020 9
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Figure 5. Deficiency of PLOD2 Inhibited Metastasis of SCC Cells In Vivo
(A) In vivo development of metastatic foci inside thoracic cavity in mice xenografted with GFP-expressing HSC-2 bearing PLOD2-WT (left panel) and the
PLOD2-deficient HSC-2 (PLOD2-KO; right panel). Fluorescence imaging was performed 40 days post-implant.
(B) Histological examination of the metastatic tumor with wild type of PLOD2 (PLOD2-WT) and of that without PLOD2 (PLOD2-KO) in mice tumor models.
Immunohistochemistry using anti-PLOD2 Ab and anti-integrin b1 Ab were performed in the same tumor. Box at the HE images (upper panel) indicated the
field shown as hyperview in the middle and lower panel. Scale bar = 50 mm.restored cellular motility, which was similar to the original HSC-2 by regaining expression of maturated
integrin b1 (Figures S9A and S9B). This corroborated requirement of integrin b1 expression for invasive
property of HSC-2 cells, and it was regulated by PLOD2. Further we performed the time-dependent chase
experiment for integrin b1 under presence of PLOD2 on PLOD2-KO clone with or withoutWT-PLOD2 and
DPKHD-PLOD2 transfection. Result showed significant induction of mature integrin b1 was detected in
response to time-dependent increase of WT-PLOD2 (Figure S10). Whereas overexpression of DPKHD-
PLOD2, deficient form of hydroxylation activity (Figure 4B), induced the instability of integrin b1, which sug-
gested the necessity of hydroxylation for integrin b1 maturation. Consequently, in the tumor metastasis
mouse model, implant of the PLOD2-KO (KO#31) HSC-2 clone showed drastic elimination of metastatic le-
sions inside the thoracic cavity in vivo except for local growth of lung tumors, which was clearly different
from the PLOD2-WT cell-implanted mice with multiple metastatic foci on pleura (Figures 5A and S11).
Immunohistochemistry of the tumors derived from the PLOD2-WT cell-xenograft and KO#31 cell-xenograft
was corroborative with tumor cells with or without coexpression of PLOD2 and functional integrin b1
(Figure 5B).Coexpression of PLOD2 and Integrin b1 in Oral, Pharyngeal, and Laryngeal SCC Tissues from
the Patients
Finally, endogenous expression of PLOD2 and integrin b1 in SCC tissues from patients was examined. As
shown in Figure 6, enhanced expression of PLOD2 was detected in SCC cells from different origins such as
oral cavity (case 1, case 2: well-differentiated type; case 3: moderately differentiated type), pharynx (case 4:
well-differentiated type; case 5: moderately differentiated type), and larynx (case 6: moderately differenti-
ated type), which was consistent and coincident with integrin b1 expression, especially at the marginal re-
gion and invasive front of the tumor nests (Figure S12A). Moreover, we demonstrated coexpression of
these two proteins at invasive cancer nest using double immunofluorescence (Figure S12B).DISCUSSION
Intracellular molecules undergoing hydroxylation by various hydroxylases have been reported to signifi-
cantly alter cellular functions by regulation of protein degradation, resulting in translational activation or
repression of particular proteins in various cancer cells. These intracellular events consequently affect
cell-cycle progression, gene expression and activation, and the triggering of cancer invasion/metastases
(Ploumakis and Coleman, 2015; Ivan et al., 2001; Zhang et al., 2009; Singleton et al., 2014). Previous studies
have shown that PLOD2, one of the lysine hydroxylases, which is highly expressed in cancer cells, plays a
major role to process collagens as substrate to form a suitable tumor ECM (Chen et al., 2015; Gilkes
et al., 2013a, 2013b; Eisinger-Mathason et al., 2013). Accordingly, previous reports on the biological signif-
icance of PLOD2 in tumors focused on ECM regulation through its interaction with collagen fibers
comprising the tumor matrix.
In this study, we found an additional functional aspect of PLOD2 as a direct regulator of cancer invasion/
metastasis through its specific interaction with a major integrin family molecule, integrin b1. Namely,
PLOD2 is a key regulator for activation of integrin b1 expressed in head and neck SCCs, which stabilizes
and activates integrin b1 by hydroxylation via specific binding. This event leads to accelerated cellular
motility needed to form metastatic sites for the SCC cells in vivo. Based on results of our analysis, tumor
invasion via the PLOD2-mediated activation of integrin b1 seems not to be mediated by the EMT (epithe-
lial-mesenchymal transition) process in cancer cells but by the direct effect of interactions of these twomol-
ecules. Marked increase in cellular motility of SCC cells was observed by integrin b1-PLOD2 protein-protein
interaction without altering CDH1 or SNAIL expression (Friedl, 2004; Friedl et al., 2004; Canel et al., 2013) as
shown in Figure 2C, and the increase appeared strongly affected by catalytic activity of PLOD2 (Figures 2G,
2H, and 4D). Importantly, instability of integrin b1 protein from knockdown of PLOD2 (downregulation of
PLOD2) was observed in cancer cells of diverse origins such as esophageal SCC cells (KYSE30), lung adeno-
carcinoma cells (A549), uterine cervical SCC cells (HeLa), hepatocellular carcinoma cells (KYN-2), and breastiScience 23, 100850, February 21, 2020 11
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Figure 6. Expression of PLOD2 and Integrin b1 in Head and Neck SCCs from the Patients
Immunohistochemistry using anti-PLOD2 Ab and anti-integrin b1 Ab were performed on the SCC tissues derived from oral cavity, pharynx, and larynx,
respectively. Box at the HE images (left column) indicated the field shown as hyperview in the middle and right column. Scale bar = 50 mm.invasive ductal adenocarcinoma cells (MCF7) as well (Figure S13A). In addition, we examined change of in-
tegrin b6 and integrin a5 expression by treating with PLOD2-siRNA in HSC-2, HSC-3, and Ca9-22 cells,
because integrin b6 and a5 were reported to be expressed, in addition to b1 on head/neck SCCs (Koivistro
et al., 2000). The result was shown as Figure S13B, which demonstrated significant attenuation of integrin b6
and a5 by PLOD2-siRNA treatment in these cells. As an exception, in HSC-3 cells, unlike other two SCC
lines, decrease of a5 was not clearly observed, whereas integrin b6 was decreased as well as b1. This might
be because of the HSC-3’s different cellular property from HSC-2 and Ca9-22 (both were cloned from pri-
mary SCC lesion), which was cloned from the lymph nodal metastasis and with highly expressed Vimentin
(Figure 2C). These observations imply that PLOD2 might play a pivotal role for regulation of integrin b1
involved in invasion/metastasis of tumors with diverse lineages. Additionally, integrin b1 knockdown had
less of an effect on migration in Figure S4B, than siPLOD2 throughout. PLOD2 may in fact provide an
approach to target integrin b1 along with some other invasion-promoting targets. A large screening for
PLOD2 targets may be required in the future.
We demonstrated that PLOD2 hydroxylase modified integrin b1 protein as a direct substrate. In the intra-
cellular molecular binding assay (Fluoppi assay), PLOD2 and integrin b1 formed complex at the ER (ER) as
shown in Figures 3B, 3C, and S6, then the integrin b1 moved to filopodia and the plasma membrane (Fig-
ure 3D). ER localization of PLOD2 has been reported in the previous studies (Chen et al., 2017; Gjaltema
et al., 2016), which is consistent with our present result, indicating that PLOD2 first hydroxylizes integrin
b1 at the ER, following which the integrin b1 is recruited to the cell surface functional site after the
modification.
In previous studies on modification of collagen by PLOD2, hydroxylation of lysine within the X-K-G motif was
reported to be essential for polymerization of collagen fibers (Kivirikko and Pihlajaniemi, 1998; Myllyharju and
Kivirikko, 2004; Takaluoma et al., 2007; van der Slot et al., 2003). Based on earlier findings, the putative lysine-
rich motif for hydroxylation was found at position of #651-658 a.a., ‘‘AFNKGEKK,’’ in integrin b1 (Figure S13C),
which may point to a target motif for PLOD2. In fact, the mass spectrometry result revealed ‘‘AFNKGEKK’’ as
the supershifted peak among integrin b1 fragments, which appeared only in the active PLOD2-treated sample
(Figures 4A and 4B), and coincidently, the triple Lys substitution with Ala (K654A/K657A/K658A) abolishedmem-
brane localization of integrin b1 (Figures 4F and S7). Taking these together, the hydroxylation of these lysine
within AFNKGEKK sequence by PLOD2 is critically implicated in gain of integrin b1 function in vivo.
We generated the PLOD2-knockout HSC-2 clone, PLOD2-KO (KO#31; heterozygous genomic knockout of
PLOD2, PLOD2/+), and tracked its dynamics in vivo in comparison with those of the parental HSC-2 (wild
type; PLOD2-WT) using the mouse xenografted model. Intrathoracic implant of PLOD2-KO cells showed
loss of pleural dissemination and pulmonary metastasis; it only showed local growth of tumor, whereas
PLOD2-WT cells developed multiple metastatic foci covering the entire thoracic cavity. These data sug-
gested that cancer cell motility was critically regulated by the presence of PLOD2. Immunohistochemistry
demonstrated coexpression of PLOD2 and integrin b1 at invasive cancer nests in the metastatic tumor tis-
sue derived from the mice implanted with PLOD2-WT cells, whereas integrin b1 expression in cancer nests
was markedly attenuated by defect in PLOD2. This histological finding corroborated the significant rela-
tionship between integrin b1 and PLOD2 in vivo as was proven, further, by in vitromolecular assay. Finally,
we confirmed that the expression pattern of integrin b1 and PLOD2 in SCC tissues surgically obtained from
patients was similar to that of tumors in the mouse model.
Therefore, we conclude that integrin b1, a critical motor molecule for SCC invasion/metastasis, requires
PLOD2 for its stabilization and functional cellular localization via their specific interaction through hydrox-
ylation (Figure 7). Our results indicate that specific suppression of PLOD2 activity may provide one of the
chief clues for inhibiting cancer invasion/metastasis in future cancer therapeutics.Limitations of the Study
This study provides a crosstalk between PLOD 2 and integrin b1 in cellular motility, and the hydroxylation
on integrin b1 by PLOD2 is critical for its intracellular stability. However, we could not optimize the in vitroiScience 23, 100850, February 21, 2020 13
Figure 7. Intracellular Dynamics of Integrin b1 Mediated by PLOD2 in SCC Cells
Head and neck squamous cell carcinomas retain high-level expression of PLOD2, which induces hydroxylation of integrin
b1. Integrin b1 protein is stabilized by the hydroxylation and recruited to cell membrane as its functional site, which
contributes to invasion/metastasis of SCCs. Loss of PLOD2 by contrast causes instability of integrin b1, which results in
loss of tumor metastasis. PM (plasma membrane), ER (endoplasmic reticulum), integrin a (yellow), and b1 (red).reaction of integrin b1 hydroxylation, because of an insoluble integrin b1 mutant substrate, and we were
unable to directly detect the function of PLOD2 and integrin b1 in patient-derived primary SCC samples.
Further enzymatically and clinically studies remain to be determined.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100850.
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Figure S1. Cell growth and migration by the suppression of PLODs, Related to Figure 1.
(A) mRNA expression of the protein hydroxylases was semi-quantitatively examined in oral SCC lines (HSC-2,
HSC-3 and Ca9-22) and non-neoplastic keratinocytes (HaCaT) by RT-PCR. (B) Effects of two different oligos for
PLOD2 knockdown were confirmed by immunoblot and wound healing assay. #1: custom siRNA synthesis based on
previously reports (Sada et al., 2016). #2: on-target plus siRNA (set of 4 oligos). (C) Oral SCC cell growth was
measured by MTT assay 48 hours after transfection of siRNA. Data are means±s.d. from 3 biological replicates.
(D) Distribution of integrin b1 (red) by the knockdown of PLOD1 and PLOD3 gene. Cytoskeleton (green) and
nuclei (blue) were stained with phalloidin and Hoechst, respectively. Scale bar = 20 mm
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Figure S2. Membrane localization of CDH1 and integrin b1 in the PLOD2-knockdown oral cancer cells,
Related to Figure 2.
(A) Representative images of plasma membrane localization of CDH1 (red). Plasma membrane was marked
with GFP (green) using a CellLight membrane-GFP. Membrane localization of CDH1 merged with GFP were
quantified by fluorescence intensity (right panel). Quantitative results are mean±s.d. from 3 biological
replicates with more 10 cells per replicates (n.s. = not significant, Student’s t-test). Non-targeting siRNA (siCtrl)
and siPLOD2 are shown by gray and white box, respectively. Scale bar = 20 mm (B) PLOD2-knockdown cells
were stained for integrin b1, and filopodial protrusions (magenta) were detected by FiloQuant (Jacquement et
al., 2017) as a plugin for the ImageJ. Protrusion number (right panel) was quantified by FiloQuant analysis.
Results are mean±s.d. from 3 biological replicates with 20 - 50 cells per replicates (*p < 0.05, Student’s t-test).
Scale bar = 20 mm (C) Representative images of plasma membrane localization of integrin b1 (red). Plasma
membrane was marked with GFP (green) using a CellLight membrane-GFP. Fluorescence intensity of integrin
b1 localized membrane was calculated and the results are mean±s.d. from 3 biological replicates with more 10
cells per replicates (*p < 0.05, Student’s t-test). Scale bar = 20 mm
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Figure S3. Intracellular localization of integrin b1, Related to Figure 2.
Magnification of image in Figure 2B. Scale bar = 10 mm.
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Figure S4. Expression of integrin b1 in the PLOD2-knockdown oral cancer cells, Related to Figure 2.
(A) The intensity of immunoblot band (Fig. 2C) was quantified by densitometric analysis. Band intensity was
normalized to beta-Actin band intensity. Data are means±s.d. from 3 biological replicates (*p < 0.05, Student’s t-
test). (B) Cell migration was detected by wound healing assay after transfection of integrin b1 siRNA (sib1). Images
were taken 0 and 24 h after wound formation (scale bar = 400 mm), and the wound width was estimated using
fluorescence microscopic images. Data are means±s.d. from 3 technical replicates for 1 biological replicate (*p <
0.05, Student’s t-test as compared to siCtrl). (C) Expression of integrin b1 in the sib1-transfected cells by
immunoblotting using anti-integrin b1. Band intensity was normalized to beta-Actin band intensity. Data are
means±s.d. from 3 technical replicates for 1 biological replicate (*p < 0.05, Student’s t-test).
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Figure S5. Ueki et al 
Figure S5. Distribution of integrin b1 by PLOD2 expression, Related to Figure 2.
(A) The intensity of immunoblot band (Fig. 2F) was quantified by densitometric analysis. Band intensity was
normalized to beta-Actin band intensity. Data are means±s.d. from 3 biological replicates (*p < 0.05, Student’s t-
test). (B) Representative images of plasma membrane localization of integrin b1. Distribution shift of integrin b1
were quantified by fluorescence intensity of intracellular and plasma membrane-localized b1. Quantitative results are
mean±s.d. from 3 biological replicates with more 10 cells per replicates (*p < 0.05, Student’s t-test). Scale bar = 20
mm (C) The percentages of lysosome localization of integrin b1 were calculated by immunofluorescence image of
b1 overlap with lyso-GFP vs total b1. Pearson’s correlation coefficient was used to measure correlation between
integrin b1 and lysosome. Quantitative results are mean±s.d. from 3 biological replicates with more 10 cells per
replicates (n.s. = not significant, Student’s t-test). (D) HSC-2 cells were transfected with the expression vector of
ΔPKHD-PLOD2 cloning to pEF1a-IRES-ZsGreen. After 24h, the cells were treated with MG132. The expression
levels and subcellular localization of integrin b1 were observed by immunoblot and immunocytochemical analysis.
Scale bar = 20 mm
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Figure S6. The interaction of integrin b1 with PLOD2 in endoplasmic reticulum, Related to Figure 3.
(A) The protein-protein interaction between PLOD2 and integrin b1 was detected using the fluorescent-based
Fluoppi system. Representative images of intracellular foci were observed at high-resolution by the fluorescence
microscopy. Scale bar = 10 mm (B) The fluorescence intensity per unit area of foci was measured. Data are obtained
as the averages of nine spots from three independent biological replicates. Error bar represent s.d. (*p < 0.05,
Student’s t-test). (C) Marked aggregation of fluorescent dots was detected only in the PLOD2-knockout HSC-2 cells
cotransfected with integrin b1-Red and PLOD2-Ash. Nuclei (blue) were stained with Hoechst. Results represent the
three images from three independent biological replicates. Scale bar = 20 mm (D) Lysate (Input) from HSC-2 cells
was immunoprecipitated (IP) with control IgG or anti-PLOD2 antibody. Endogenous integrin b1 was coprecipitated
with endogenous PLOD2 in HSC-2 cells.
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Figure S7. PLOD2 activity and plasma membrane translocation of integrin b1, Related to Figure 4.
(A) BHK (baby hamster kidney) cells were transfected with empty control vector, WT-integrin b1 (WT) and mutant
integrin b1 (triple KA). Expression of integrin b1 was confirmed by immunofluorescence staining without
permeabilization. Scale bar = 20 mm (B) Flow-cytometry analysis of integrin b1 expression in transfected BHK
cells without permeabilization. Cells were gated on the basis of their SSC and FSC (upper panels). In dot plot
(middle panels), the boxed area shows the positive populations of cell surface. Histogram and mean fluorescence
intensity (MFI) shown in lower panels.
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Figure S8. Analysis of PLOD2 KO cells, Related to Figure 5.
(A) Sequence of Exon 7 in PLOD2 gene targeting by CRISPR-Cas9 system. PLOD2 knockout cells (KO #2, #31)
were isolated as heterozygous deletion and frameshift mutation. gRNA (guide RNA) for using CRISPR-Cas9 system
are shown. (B) Cell growth of PLOD2-KO HSC-2 cell was measured by MTT assay. Results are mean±s.d. from 3
biological replicates. (C) Expression of PLOD2 and integrin b1 in the PLOD2-knockout cells were examined by
immunoblotting. (D) Distribution of integrin b1 (red) and E-cadherin (CDH1: green) by the knockout of PLOD2
gene. Scale bar = 20 mm (E) Cell migration of PLOD2-knockout cell lines was detected by wound healing assay
using 24-well plate coated with collagen. Images were taken 0, 24 and 48 h after wound formation (scale bar = 400
mm), and the wound width was estimated using microscopic images. Results are mean±s.d. from 3 technical
replicates for 1 biological replicate (*p < 0.05, , Student’s t-test as compared to WT).
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Figure S9. Integrin b1 maturation by re-expression of PLOD2 in PLOD2-knockout cells, Related to
Figure 5.
(A) After stable transfection of empty control vector or WT-PLOD2 to PLOD2-knockout cells (KO #31), the cells
were selected with G418 for 4 weeks. Stable cell lines expressing PLOD2 and ZsGreen were generated. These
revertant cell lines (revCtrl clone #1, #2 and revPLOD2 clone #3, #5) were seeded and cultured in 24-well plates for
48 hours. Re-expression of PLOD2 and integrin b1 were detected by immunoblotting. The intensity of immunoblot
band (right panel) was quantified by densitometric analysis. Band intensity was normalized to beta-Actin band
intensity. Data are means±s.d. from 3 biological replicates (*p < 0.05, Student’s t-test). (B) Migration rate of
revertant cells was measured by wound healing assay. Images were taken 0, 24 and 48 hours after wound formation
(scale bar = 400 mm), and the wound width was estimated using fluorescence microscopic images. Data are
means±s.d. from 3 technical replicates for 1 biological replicate (*p < 0.05, Student’s t-test between revCtrl and
revPLOD2).
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Figure S10. Integrin b1 maturation in a PLOD2-dependent manner, Related to Figure 5.
(A) PLOD2-knockout cells (KO #31) were transiently transfected with empty control vector (upper panel), WT-
PLOD2 (middle panel) and ΔPKHD-PLOD2 (lower panel). Cell lysate was collected at each time points after
transfection, and the expression of integrin b1 and PLOD2 were detected by immunoblotting.
(B) The intensity of immunoblot band was quantified by densitometric analysis. Band intensity was normalized to
beta-Actin band intensity. Each band intensity of empty vector, WT-PLOD2 and ΔPKHD-PLOD2 overexpression are
shown by blue, red and green box, respectively. Data are means±s.d. from 3 biological replicates (*p < 0.05,
Student’s t-test as compared to empty vector).
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Figure S11. Fluorescence imaging of PLOD2 KO cells in vivo, Related to Figure 5.
Fluorescence imaging of the invasive and metastatic tumors in the thoracic cavity of mice injecting PLOD2-WT and 
PLOD2-KO HSC-2 cells are shown. Scale bar = 50 mm
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Figure S12. Colocalization of PLOD2 and integrin b1 in the SCC tissues, Related to Figure 6
(A) Immunohistochemistry using anti-PLOD2 Ab and anti-integrin b1 Ab were performed on the SCC tissues
derived from larynx and oral cavity. Box at the HE images (left panel) indicated the field shown as hyperview in the
middle and lower panel. Scale bar = 1 mm (B) Subcellular colocalization (lower panels, arrowhead) of PLOD2
(green) and integrin b1 (red) in each case of oral SCC was assessed by fluorescent immunostaining using anti-
PLOD2 and anti-integrin b1 antibodies. Nuclear counterstain with Hoechst 33258 was applied. Results represent the
images from five independent area for the three cases. Scale bar = 20 mm
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Figure S13. Expression of integrin b1 in PLOD2-knockdowned cancer cells, Related to Figure 4.
(A) Expression levels of integrin b1 in PLOD2 siRNA-transfected cancer cell lines were detected by
immunoblotting. KYSE30 (esophageal cancer), A549 (lung cancer), HeLa (cervical cancer), KYN2 (liver cancer)
and MCF7 (breast cancer) were used. (B) Expression of integrin b1, b6 and a5 in the PLOD2-knockdowned cells
were examined by immunoblotting. (C) Amino acid sequence of integrin b1. Hydroxylation site (box),
transmembrane domain (dashed line) and cytoplasmic domain (under line) are shown.
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Gene name Forward primer (5’ to 3’) Reverse primer (5’ to 3’)
Primer sets of quantitative real-time PCR
ALKBH3 TGGCTTTGTTGACGTGAAAG GTGCCAGTGAGGATTTGGTT
ASPH GGGAGATTTTATTTCCACCTGGG CCTTTGGCTTTATCCATCACTGC
EGLN1 GCCCAGTTTGCTGACATTGAAC CCCTCACACCTTTCTCACCTGTTAG
EGLN2 AGCCCCTAAGTCAGGCTCTC AGTGGTAGAGGTGGCTGTGG
EGLN3 ATCGACAGGCTGGTCCTCTA CTTGGCATCCCAATTCTTGT
FIH1 GTGGGCAGGAAGATTGTCAT GGGTGATGAACAGGGTATGG
FTO GAGAGCGCGAAGCTAAGAAA AATGAGGATGCGAGATACCG
ITGB1 AATGAAGGGCGTGTTGGTAG CGTTGCTGGCTTCACAAGTA
JMJD2A CCTCACTGCGCTGTCTGTATGATC CCAGTCGAAGTGAAGCACATTTC
JMJD6 GGCACAACTACTACGAGAGC TTTGGCACCTTGTAGTCTTCC
MINA53 TACTTTGGCTCCTTGGTTGG GGAGTGTCCGCTTGATGAAT
NO66 TGTTTACGGGCTTCCAATTC TCCCCCACTCTCACAAACTC
OGFOD1 TTTGAAGATTTCCGGTCCTGG GACCATGAAACCAGCCACTT
PLOD1 GCAGCAGGATGTGTTCATGT GGGCTTTGGTGTAGTTCTGG
PLOD2 GCGTTCTCTTCGTCCTCATC GTGTGAGTCTCCCAGGATGC
PLOD3 GGTACGAGGACCAGTGGCT GAAGGTGGATGAGTCGTGGT
TET1 GGGCAGTGGAAAAGAAACCT GGGGTTCGGTTTCACTTTTT
beta-Actin CCTCATGAAGATCCTCACCGA TGCCAATGGTGATGACCTGG
Primer sets of Cloning and plasmid construction
PLOD2-WT
for pEF1-IRES-ZsGreen
TTACTAGTGCCATGGGGGGATGCACG 
GTGAAG
ACCCGGGGGATCTATAAATGACACTGC
PLOD2-WT
for pcDNA3.1(+)
Same forward primer 
with PLOD2-WT
TTGCGGCCGCTCAGAGGTCTTCTTCTG
AGAT
PLOD2-ΔPKHD
for pEF1-IRES-ZsGreen
Same forward primer 
with PLOD2-WT
ACCCGGGAAATATGGGGAACCAAAAGA
C
PLOD2-ΔPKHD
for pcDNA3.1(+)
Same forward primer 
with PLOD2-WT
TTGCGGCCGCTCAGAGGTCTTCTTCTG
AGAT
PLOD2-Red
for pMonti-Red-MNL
GGGAAGCTTACCATGGGGGGATGCAC
GGTGAAG
GGCGGCCGCGGGATCTATAAATGACAC
TGC
Integrin b1-WT
for pcDNA3.1(+)
GGGGGATCCACCATGAATTTACAACC
AATTTTCTG
TCTCTCGAGCTTTTCCCTCATACTTCG
GATTGAC
Integrin b1-Ash
for pAsh-MNL Ver.2
Same forward primer 
with ITGB1-WT
AGCGGCCGCTTTTCCCTCATACTTCGG
ATTGA 
EGFP
for pcDNA3.1(+)
TTTCTCGAGGTGAGCAAGGGCGAGGA
GCTGTTC
CGCGGGCCCTTACTTGTACAGCTCGTC 
CAT
Annealing oligonucleotides
Myc-tag
for PLOD2-WT & ΔPKHD
GGGGGATCCGGCGGAGGGGAGCAGAA  
GCTCATCTCAGAAGAAGACCTCTGAT 
GATCATCAGAGGTCTTCTTCTGAGATG
AGCTTCTGCTCCCCTCCGCCGGATCCC
CC
FLAG-tag
for Integrin b1-WT & 
mutants
TCGAGACTACAAAGACGATGACGACA
AGTAATAGGCC
TATTACTTGTCGTCATCGTCTTTGTAG
TC
Myc-tag for EGFP
CTAGCACCATGGAGCAGAAGCTCATC 
TCAGAAGAAGACC
TCGAGGTCTTCTTCTGAGATGAGCTTC
TGCTCCATGGTG
Table S1. Oligonucleotides, Related to Figures 1 – 4.
 TRANSPARENT METHODS 
Cell lines 
Human cancer cell lines used in the present study were as follows: HSC-2, HSC-3, 
derived from the lymph nodes of different patients with metastatic poorly differentiated 
SCC, and Ca9-22 derived from the patients with gingival SCC (JCRB Cell Bank: 
Japanese Collection of Research Bioresources Cell Bank) (Yamamoto et al., 1986; 
Momose et al., 1989; Matsui et al., 1998). Cells were maintained in RPMI 1640 
containing 10% FBS with 100 unit/mL penicillin and 100 mg/mL streptomycin (Life 
Technologies) at 37℃ with 5% CO2. These cell lines were passaged for less than 6 
months and then replaced with those of early passages. 
 
PLOD2 KO cell lines 
PLOD2 knockout cell clones were generated by CRISPR/Cas-9 based genome 
engineering technology. The plasmids hCas9 and gRNA_Cloning Vector were a gift 
from George Church (Addgene plasmid # 41815 and #41824) (Mali et al., 2013). gRNA 
vector including PLOD2 targeting sequence (5’- GCTGATCATCATCATTATCC -3’) 
was prepared by following Church lab protocol (https://media.addgene.org/41824/). 
hCas9 and PLOD2 gRNA vector were co-transfected into cells using Lipofectamine 
 3000 Transfection Reagent (Thermo Fisher Scientific) by following manufacturer’s 
protocol. Single cell cloning was achieved by serial dilution, and genotype of each 
clones was analyzed by genomic PCR followed by Sanger DNA sequencing. Following 
primers were used to amplify genomic sequence including PLOD2 targeting site, 
forward primer: 5’-TCCCTTAGGAGCCTTGGAAAACA and reverse primer: 
5’-ATCCAGCCAGGTGACATAAACCA. Sanger DNA sequencing was carried out 
using the forward primer and BigDye terminator v3.1 cycle sequencing kit (Applied 
Biosystems).  
For revertant cell lines re-expressing PLOD2 in PLOD2-knockout cells, the 
PLOD2-IRES-ZsGreen plasmid was transfected into PLOD2-knockout cells. After 
selection with 0.1 mg/ml of Geneticin (G418, Gibco) for 4 weeks, PLOD2 re-expressing 
stable lines were newly cloned. 
 
Animal models 
A total of 1.0×106 cells of human oral squamous cell carcinoma cell lines stably 
expressing Green fluorescent protein (GFP-HSC-2) were transplanted into the pleural 
cavity of a 7-week-old female nude mice (BALB/c nu/nu, CLEA Japan Inc.) by direct 
injection. 40 days after initial administration of the GFP-HSC-2 cells, all mice were 
 autopsied and their organs examined by fluorescence stereomicroscopy (Leica M165 
FC).  
The animal studies in the present work were approved by the Animal Research 
Committee of the Niigata University School of Medicine. All mouse procedures and 
euthanasia, including cell transplantations, were performed painlessly or under 
anesthesia, and within the strict guidelines of the Experimental Animal Center of 
Niigata University School of Medicine. 
 
Plasmid construction and transfection 
cDNA were prepared from HSC-2 cells using an RNeasy kit (Qiagen) and a Super 
Script III kit (Invitrogen). Human PLOD2 CDS (NM_000935.2) and Integrin 1 CDS 
(NM_002211.4) were amplified from HSC-2 cDNA and NHDF cDNA, respectively. 
They were cloned into pBluescript SK+ vector (Stratagene). To generate the PLOD2 
wild type and mutant plasmid, PLOD2 genes were subcloned into a 
pEF1-IRES-ZsGreen vector at the Nhe I / Spe I compatible cohesive sites and Sma I site. 
The synthetic myc-tag oligonucleotides were annealed and inserted into a 
pEF1-IRES-ZsGreen (Clontech) vector at the Sma I and BamH I site. Furthermore, 
PLOD2-myc gene were subcloned into a pcDNA3.1(+) at the Nhe I / Spe I compatible 
 cohesive sites and Not I site. For integrin 1-FLAG plasmid, integrin 1 gene were 
subcloned into a pcDNA 3.1(+) vector (Thermo Fisher Scientific) at the BamH I - Xho I. 
The synthetic flag-tag oligonucleotides were annealed and inserted into a pcDNA 3.1(+) 
vector at the Xho I and Apa I site. For Myc-EGFP plasmid, EGFP gene were amplified 
from the pEGFP-N1 vector (Clontech) and subcloned into a pcDNA 3.1(+) at the Xho I 
- Apa I site. The synthetic myc-tag oligonucleotides were annealed and inserted into the 
Nhe I-Xho I sites. 
PLOD2-Red plasmid was constructed by cloning the cDNA encoding PLOD2 into 
the Hind III - Not I of the vector pMonti-Red-MNL (MBL). Integrin 1-Ash plasmid 
was constructed by cloning the cDNA encoding integrin 1 into the BamH I - Not I of 
the vector pAsh-NML Ver.2 (MBL). 
The site-directed mutagenesis for integrin 1 was performed by PCR using a single 
mutant primer and PfuUltra High-Fidelity DNA polymerase (Agilent Technologies). 
After Dpn I digestion the PCR products were transformed into the competent E.coli 
cells. The nucleotide sequences of all constructs obtained by PCR were confirmed by 
DNA sequencing. The primer sets used in this study are shown in Table S1. 
For the plasmid transfection, Cells were transiently transfected with PLOD2 and 
integrin 1 plasmids using Lipofectamine 3000 (Thermo Fisher Scientific) according to 
 the manufacturer’s instructions. The stable clone expressing EGFP was selected in 0.6 
mg/ml of Geneticin (Gibco). 
 
Cell proliferation assay 
Cells (4×104) were seeded on a 48-well plate. After 48 hours of siRNA transfection, 
cell proliferation was evaluated by MTT assay using Cell Count Reagent SF (Nacalai 
Tesque) according to the manufacturer’s protocol. 
 
Wound healing assay 
The myc-EGFP plasmid was transfected into HSC-2, HSC-3 and Ca9-22 cells. After 
selection with 600 g/ml of Geneticin for 4 weeks, GFP-expressing stable lines were 
newly cloned and used in wound healing assay. Cells were seeded in collagen type-1 
coated 24-well plates. 48 hours after siRNA treatment was made a scratch using a cell 
scratcher was done (Iwaki, Asahi Technoglass). The wounded monolayer was washed 
with PBS, exchanged medium, and photographed using a microscope every time. All 
data were obtained from at least three independent experiments. 
 
Conventional and quantitative PCR 
 Total RNA was extracted from prepared cells using RNeasy plus mini kit (QIAGEN) 
according to the manufacturer’s protocol. Complementary DNA was synthesized from 1 
µg of total RNA using Revertra Ace (Toyobo) for performing mRNA analysis. Each 
cDNA was amplified by PCR with z-Taq polymerase (TaKaRa). Quantitative real-time 
PCR was performed using SYBR Green RT-PCR Kit (Applied Biosystems). Data 
analysis was followed by ∆∆CT methods using the step one plus instruction (Applied 
Biosystems). The primer sets used in this study are described in Supplementary Table 
S1. 
 
RNA interference 
Each siRNA (25 nM) was transfected using Lipofectamine RNAi MAX reagent 
(Thermo Fisher Scientific) according to the manufacturer’s protocol. ON-TARGET plus 
SMART pool siRNA for human PLOD2 (#5352), PLOD1 (#5351) and PLOD3 (#8985) 
were purchased from Dharmacon. The custom siRNA of PLOD2 (Sada et al., 2016) and  
integrin 1 (Kato et al., 2014) was synthesized by Sigma-Aldrich. Negative control 
scrambled siRNA was purchased from Sigma-Aldrich. 
 
Immunoblotting and immunoprecipitation 
 The cell pellets were lysed with the RIPA buffer (50 mM Tris/HCl pH 7.5, 150 mM 
NaCl, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS) containing the complete mini 
protease inhibitor (Roche). Samples were separated on 10% SDS-PAGE gels followed 
by transfer to PVDF membrane. Nonspecific binding was blocked by incubation in 5% 
skim milk in TBS-T. Blots were probed with specific primary antibodies followed by 
appropriate horseradish peroxidase-conjugated secondary antibody. Positive signals 
were detected by a chemiluminescence system (Supersignal West Pico or Femto 
substrate; Thermo Fisher Scientific) and quantification of band intensity was calculated 
using a ChemiDoc Touch imager (Bio-Rad). Anti-PLOD1 (Sigma-Aldrich), 
anti-PLOD2 (Proteintech), anti-PLOD3 (Sigma-Aldrich), anti-Integrin 1 (CST) 
anti-E-cadherin (BD Biosciences), anti-SNAIL (Abcam), anti-ZO-1 (Abcam) 
anti-Vimentin (Santa Cruz Biotechnology) and anti-Actin (Merck) antibodies were used 
for immunoblotting. 
For immunoprecipitation, HEK 293T cells were transiently co-transfected with the 
expressor plasmid of integrin 1-flag and PLOD2-myc. Cells were lysed in IP buffer 
(50 mM Tris-HCl pH7.5, 150 mM NaCl, 1% Brijo 20, 0.5% n-octyl--D-glucoside, 
0.5% Triton-X, 1 mM PMSF) supplemented with protease inhibitors cocktail (Roche). 
Cell lysates were incubated overnight at 4℃ with anti-FLAG M2 affinity gel 
 (Sigma-Aldrich). Beads were washed six times with wash buffer (50 mM Tris-HCl 
pH7.5, 150mM NaCl, 0.2% NP-40) and were boiled in 2× sample buffer (125 mM 
Tris-HCl pH 6.8, 4% SDS, 20% Glycerol, 0.01% Bromophenol blue, 10% 
-Mercaptoethanol). Equal amounts of proteins were separated on 10% SDS-PAGE gels 
and immunoblotted with the anti-myc monoclonal antibody (9E10, Sigma-Aldrich) and 
horseradish peroxidase-conjugated secondary antibody (Mouse TrueBlot ULTRA: 
anti-mouse Ig HRP, Rockland). 
 
Fluoppi assay 
  The protein-protein interaction between PLOD2 and integrin 1 was detected using 
the fluorescent-based technology detecting protein-protein interaction (Fluoppi) system 
(MBL life science), in which PPIs were visualized as foci (Koyano et al., 2014; Yamano 
et al., 2015). PLOD2 was subcloned into a pMonti-Red-MNL plasmid to fuse with a 
Monti-Red (homo tetramer red fluorescent protein from Montipora sp.) tag. Integrin 1 
was subcloned into a pAsh-MNL ver.2 plasmid to fuse with an Ash (homo oligomerized 
protein assembly helper) tag. These plasmids of PLOD2-Red and integrin 1-Ash were 
co-transfected into HSC-2 or HeLa cells using Lipofectamine 3000 (Thermo Fisher 
Scientific) according to the manufacturer’s instructions, and intracellular foci were 
 observed by the Olympus IX71 fluorescence microscope and analyzed using cellSens 
standard software (Olympus). 
 
Mass spectrometric analysis of integrin 1 
Extracts of 5 × 106 cells expressing the integrin 1-flag and PLOD2-myc were 
prepared on ice for 30 minutes in IP buffer. Integrin 1-flag proteins were 
immunoprecipitated by using anti-FLAG M2 affinity gel and eluted by 3× FLAG 
peptide. Immunoprecipitated integrin 1-Flag were separated SDS-PAGE, the gel was 
then stained with Coomassie Blue, and protein bands corresponding to the proteins of 
interest were excised and digested with LysC protease (Roche) according to standard 
protocol. The extracted peptides were desalted and concentrated using RP-C18 StageTip 
columns and the eluted peptides used for mass spectrometric analysis. All LC/MS-MS 
experiments were performed by using standard protocol (ACROSCALE Inc. Sendai, 
Japan). Peptides were analyzed using an amaZon ETD ion trap mass spectrometer 
(Bruker Daltonics). Spectral data were compared to the Swiss-Prot Homo sapiens 
database using Mascot (version 2.3.01; Matrix Science) to identify the protein. The 
search criteria were: trypsin enzyme, allowance of up to two missed cleavage peptides, 
mass tolerance ±0.5 Da, MS/MS tolerance ±0.5 Da, fixed modifications of cysteine 
 carbamido-methylation, variable modifications of lysine hydroxylation. 
 
Flow-cytometry 
Human integrin 1 WT and triple KA mutant plasmid was transfected into BHK 
(baby hamster kidney) cells. Cells were harvested by trypsinization and washed twice 
with PBS containing 2% FBS. The cells incubated with anti-integrin 1 antibody 
(Abcam) for 20 min at 4℃, and then washed twice with PBS containing 2% FBS. For 
detection of 1 integrin, cells were incubated with anti mouse-Alexa fluor 488 (Thermo 
Fisher Scientific) for 20 min at 4℃, and further washed twice PBS containing 2% FBS. 
Cells were detected on a BD FACS Calibur cell analyzer (BD Biosciences) and data 
were analyzed using FlowJo VX software. 
 
Purification and activity of PLOD2 
PLOD2 cDNA were subcloned into the pCMVViR-TSC vector (Sakaguchi et al., 
2014) and the PLOD2-myc-6×His expressor was transfected into HEK293T cells. 
Extracts of 3 × 106 cells expressing the PLOD2-myc-6×His were prepared on ice for 30 
minutes in IP buffer. Cell lysate was load into a column of TALON metal resin (Takara) 
and washed twice with wash buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 10 mM 
 imidazole), and further eluted with 150 mM imidazole. The eluted PLOD2 was dialysed 
with 50 mM HEPES pH7.4 and 150 mM NaCl, and then concentrated with the Amicon 
ultra-0.5 centrifugal filters (Millipore). Protein concentration was estimated with the 
BCA protein assay (Pierce), Nanodorp Spectrohotometer at 280 nm (Thermo Fisher 
Scientific) and CBB staining of SDS-PAGE. 
Hydroxylation reaction of PLOD2 were carried out in 50 L volume of reaction 
buffer based on previously reported method (Guo et al., 2017). Briefly, the purified 
PLOD2 (approximately 1.0 g) was reacted with the reaction buffer (50 mM HEPES 
pH7.4, 50 M FeSO4, 100 M -KG, 500 M ascorbate, 0.125 mM peptide substrate) 
for 120 min at 37 ℃. The collagen peptide substrate (IKGIKGIKG) and integrin 1 
peptide substrate (AFNKGEKK) were synthesized at 95% purity by Scrum Inc (Tokyo 
Japan). 1 l of the reaction solution was diluted in 25 L of 50 mM HEPES pH7.4 
buffer and measured succinate production in the reaction solution using Succinate-Glo 
assay following the manufacturer’s procedure (Promega). The luminescence was 
detected using a Centro LB 960 microplate luminometer (Berthold). 
 
Immunofluorescence 
Cultured cells were fixed with PBS containing 4% paraformaldehyde and washed 
 with 0.1% Triton X-100 in phosphate-buffered saline (-). PLOD2 was stained with 
rabbit anti-PLOD2 antibody (Proteintech), Integrin 1 was stained with mouse 
anti-integrin 1 antibody (Abcam) and E-cadherin was stained with mouse 
anti-E-cadherin antibody (BD Biosciences) as a primary antibody, and further treated 
with Cy3-labeled goat anti-rabbit (H+L) antibody (Jackson), as a secondary antibody. 
Cell nuclei were counterstained with 4’,6-diamidino-2-phenylindole (Hoechst 33258 
dye; Molecular probes). CellLight ER-GFP BacMam 2.0 (Thermo Fisher Scientific) 
was used for ER marker. For the staining of actin filaments (F-actin), Alexa 
488-conjugated phalloidin (Molecular Probes) was used. The fluorescent signals were 
detected by the Olympus IX71 fluorescence microscope and analyzed using cellSens 
standard software (Olympus). For quantification, the fluorescence intensity of plasma 
membrane-localized integrin 1 vs total integrin 1 was calculated using Metamorph 
software (Molecular devices). Colocalization analysis and calculation of filopodial 
protrusions were performed using a Coloc 2 and FiloQuant (Jacquement et al., 2017) as a 
plugin for the ImageJ software. CellLight Membrane-GFP BacMam 2.0 (Thermo Fisher 
Scientific) was used for plasma membrane marker. 
 
Immunohistochemistry and patient-derived tissues 
 Human oral, pharyngeal and laryngeal carcinoma tissues were fixed in 10% buffered 
formalin solution. Paraffin-embedded sections were deparaffinized, and antigen 
retrieval was performed by autoclaving (Pascal S2800, DakoCytomation) in sodium 
citrate buffer. Then endogenous peroxide activity was quenched by incubation in 0.3% 
hydrogen peroxide (Kanto Chemical Co.) for 20 minutes at room temperature. Slides 
were incubated with a 1:250 dilution of anti-PLOD2 antibody (Proteintech) and 
anti-integrin 1 antibody (CST) in CanGet signal immunostain solution B (Toyobo) 
overnight at 4℃, and further incubated with anti-rabbit HRP antibody (CST). After the 
slides were washed with phosphate buffered saline (-), they were subjected to the DAB 
detection system (Nichirei). 
The study using patient-derived tissues was approved by the ethics committees of 
Niigata University and Niigata Cancer Center Hospital. Informed consent for use of 
materials was also obtained from each patient. 
 
Quantification and Statistical Analysis 
Data were represented as mean ±standard deviation (s.d.). Comparisons between two 
groups were carried out using Student’s t test (MS Excel). A value of P < 0.05 was 
considered significant. 
